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Objectives The purpose of this study was to conduct a meta-analysis to examine an invasive or conservative strategy in dia-
betic versus nondiabetic patients.
Background Diabetic patients are at increased risk of cardiovascular events after an acute coronary syndrome, yet it remains
unknown whether they derive enhanced benefit from an invasive strategy.
Methods Randomized trials comparing an invasive versus conservative treatment strategy were identified. The prevalence
of cardiovascular events through 12 months was reported for each trial, stratified by diabetes mellitus status
and randomized treatment strategy. Relative risk (RR) ratios and absolute risk reductions were combined using
random-effects models.
Results Data were combined across 9 trials comprising 9,904 subjects of whom 1,789 (18.1%) had diabetes mellitus.
The RRs for death, nonfatal myocardial infarction (MI), or rehospitalization with an acute coronary syndrome for
an invasive versus conservative strategy were similar between diabetic patients (RR: 0.87; 95% confidence inter-
val [CI]: 0.73 to 1.03) and nondiabetic patients (RR: 0.86; 95% CI: 0.70 to 1.06; p interaction  0.83). An inva-
sive strategy reduced nonfatal MI in diabetic patients (RR: 0.71; 95% CI: 0.55 to 0.92), but not in nondiabetic
patients (RR: 0.98; 95% CI: 0.74 to 1.29; p interaction  0.09). The absolute risk reduction in MI with an invasive
strategy was greater in diabetic than nondiabetic patients (absolute risk reduction: 3.7% vs. 0.1%; p interaction 
0.02). There were no differences in death or stroke between groups (p interactions 0.68 and 0.20, respectively).
Conclusions An early invasive strategy yielded similar RR reductions in overall cardiovascular events in diabetic and nondiabetic
patients. However, an invasive strategy appeared to reduce recurrent nonfatal MI to a greater extent in diabetic pa-
tients. These data support the updated guidelines that recommend an invasive strategy for patients with diabetes
mellitus and non–ST-segment elevation acute coronary syndromes. (J Am Coll Cardiol 2012;60:106–11)
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July 10, 2012:106–11 An Invasive Strategy in Diabetic PatientsClinical practice guidelines recommend an invasive strategy
in patients with non–ST-segment elevation (NSTE) acute
coronary syndromes (ACS) who have high-risk features
(1,2). Although individuals with diabetes mellitus (DM) are
at increased risk of recurrent cardiovascular events, they also
have a higher prevalence of concurrent disease states that
may place them at increased risk of complications after
oronary angiography or revascularization (3,4). As such, the
elative benefit of an invasive strategy in this patient population
ith its associated comorbid conditions remains unknown.
The updated European Society of Cardiology and Amer-
can College of Cardiology/American Heart Association
uidelines have now included DM on the list of character-
stics for which an invasive strategy is preferred (1,2).
owever, the evidence to support this decision is currently
estricted to subgroup analyses presented from 2 trials (5,6).
Because individual trials have been underpowered to exam-
ine subgroups, we conducted a collaborative meta-analysis
to examine the benefit of an invasive strategy in diabetic and
nondiabetic patients with NSTE-ACS.
Methods
A total of 18 randomized clinical trials were identified
through literature review, and 9 were subsequently excluded
for prespecified criteria (Online Fig. 1). Nine remaining
trials were determined to be eligible and agreed to partici-
pate (Table 1).
The incidence of 12-month cardiovascular outcomes was
provided from each trial team in tabular format, stratified by
DM status. A diagnosis of DM was determined at the
baseline visit and captured on the case report forms. Data
were further substratified by the presence or absence of
biomarker elevation (creatine kinase–myocardial band or
troponin) or ST-segment deviation. Biomarker analyses
were restricted to those trials that enrolled patients both
with and without biomarker elevation.
Statistical analyses. A meta-analysis was performed using
random-effects models stratified by DM status, using the
method by DerSimonian and Laird (7). Effect modification
was assessed by calculating the interaction term between
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for each individual trial, combin-
ing these interaction terms in a
random-effects model, and then
testing the significance of the
combined interaction estimate.
Heterogeneity across trials was
determined using the Cochran Q
statistic (Online Appendix). All
statistical analyses were per-
formed by using Stata/SE ver-
sion 9.0 (StataCorp, College Sta-
tion, Texas). All tests were
2-sided, with p  0.05 considered significant.
Results
Across the 9 selected trials, DM status and outcome data
were available for a total of 9,904 patients. Of these patients,
1,789 (18.1%) were recorded to have a diagnosis of DM at
the time of their baseline visit. Overall, patients with DM
tended to be older and were more likely to be female, have
hypertension, hyperlipidemia, and a history of MI than
non-diabetic patients (Online Table 1). Subjects with DM
had more extensive coronary artery disease on angiography,
including a higher prevalence of 3-vessel or left main
coronary artery disease (48% vs. 31%; p  0.001). In the
invasive arm, the frequency of revascularization was similar
between groups (67.8% vs. 66.0%; p  0.31); however,
diabetic patients were more likely to have undergone coro-
nary artery bypass graft surgery (31.9% vs. 25.9%; p 
.001).
During 12 months of follow-up, the triple composite
ndpoint of incidence of death, MI, or rehospitalization
ith ACS was 30.5% in diabetic patients versus 20.3% in
ondiabetic patients (p  0.001). Patients with DM had
early a 3-fold higher rate of death (9.3% vs. 3.2%; p 
.001), and a higher rate of nonfatal MI (11.3% vs. 7.1%;
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
CI  confidence interval
DM  diabetes mellitus
NSTE  non–ST-segment
elevation
MI  myocardial infarction
OR  odds ratio
RR  relative risk
Characteristics of Trials in the Meta-Analysis*Table 1 Characteristics of Trials in the Meta-Analysis*
Trial Name
Year of
Publication N
Proportions
of Subjects
With DM, %
In-Hospital Rate
of Angiography in
the Conservative
Arm, %
TIMI IIIB 1994 782 14.6 57
MATE 1998 201 17.9 60
VANQWISH 1998 919 26.1 23
FRISC II† 1999 2,457 12.2 10
TACTICS–TIMI 18‡ 2001 2,220 27.6 51
VINO 2002 131 23.7 12
RITA 3 2002 1,810 13.5 16
ICTUS 2005 1,200 13.8 53
OASIS-5 Substudy 2012 184 25.0 40
*References and full trial names are included in the Online Appendix. †For the FRISC II trial, data
on rehospitalization with acute coronary syndromes were available for subjects enrolled in
Denmark and Sweden, representing 97% of the study population. ‡For the TACTICS–TIMI 18 trial,
data were available through 6 months.
DM  diabetes mellitus.
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An Invasive Strategy in Diabetic Patients July 10, 2012:106–11p  0.001) and rehospitalization with ACS (18.1% vs.
3.0%; p  0.001) compared with nondiabetic patients.
M status and clinical outcomes. An invasive strategy
as associated with a comparable relative reduction in
eath, MI, or rehospitalization with ACS in patients with
M (relative risk [RR]: 0.87; 95% confidence interval [CI]:
.73 to 1.03) or without DM (RR: 0.86; 95% CI: 0.70 to
.06; p interaction 0.83) (Fig. 1). In terms of the absolute
enefit of an invasive strategy, the absolute risk reduction
as 5.1% in diabetic patients compared with 3.2% in
ondiabetic patients for the triple composite endpoint
p interaction  0.24) (Table 2).
There tended to be a greater relative reduction in nonfatal
NO DIABETES Event Rates (n/N)
Invasive Conservative
TIMI IIIB 30.7% (105/342) 35.6% (116/326)
MATE 21.2% (21/99) 19.7% (13/66)
VANQWISH 29.2% (101/346) 22.8% (76/333)
FRISC II 16.5% (157/949) 27.5% (266/968)
TACTICS-TIMI 18 14.6% (117/801) 16.9% (136/806)
RITA 3 12.4% (95/765) 17.5% (140/801)
VINO 6.4% (3/47) 26.4% (14/53) 
ICTUS 21.2% (110/518) 20.0% (103/516)
OASIS 5 Substudy 17.8% (13/73) 15.4% (10/65)
OVERALL 18.3% (722/3940) 22.2% (874/3934)
DIABETES MELLITUS         Event Rates (n/N)
Invasive Conservative
TIMI IIIB 42.9% (24/56) 43.1% (25/58)
MATE 50.0% (6/12) 37.5% (9/24)
VANQWISH 40.0% (46/115) 41.6% (52/125)
FRISC II 27.1% (39/144) 41.8% (56/134)
TACTICS-TIMI 18 21.7% (68/313) 28.3% (85/300)
RITA 3 20.8% (27/130) 27.2% (31/114)
VINO 11.8% (2/17) 35.7% (5/14)
ICTUS 31.4% (27/86) 28.8% (23/80)
OASIS 5 Substudy 42.1% (8/19) 25.9% (7/27)
OVERALL 27.7% (247/892) 33.4% (293/876)
0
0.
Figure 1 Benefit of an Invasive Strategy by Diabetes Mellitus S
The relative risk (RR) of death, myocardial infarction (MI), or rehospitalization with acu
stratified by the presence (top) or absence (bottom) of diabetes mellitus. Numbe
endpoint. CI  confidence interval. References and full trial names are included inI in diabetic patients managed with an invasive strategy iRR: 0.71; 95% CI: 0.55 to 0.92) compared with non-
iabetic patients (RR: 0.98; 95% CI: 0.74 to 1.29;
interaction  0.09). Moreover, the absolute reduction in
onfatal MI risk with an invasive strategy was greater in
iabetic than nondiabetic patients (absolute risk reduction:
.7% vs. 0.1%; p interaction  0.02) (Table 2).
An invasive strategy significantly reduced the risk of
ehospitalization with ACS by 25% in patients with and
ithout DM (p interaction 0.68). By contrast, an invasive
trategy did not reduce the RR of death in either diabetic or
ondiabetic patients (p interaction  0.87) (Table 2).
iming of events. An early hazard of cardiovascular events
efore hospital discharge was observed for patients random-
RR (95% CI)
0.86 (0.70-1.07)
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RR (95% CI)
0.99 (0.65-1.52)
1.33 (0.62-2.87)
0.96 (0.71-1.30)
0.65 (0.46-0.91)
0.77 (0.58-1.01)
0.76 (0.49-1.20)
0.33 (0.08-1.45)
1.09 (0.69-1.74)
1.62 (0.71-3.71)
0.87 (0.73-1.03)
5.01.0avors invasive Favors conservative
h, MI or Rehospitalization with ACS
5.01.0avors invasive Favors conservative
ath, MI or Rehospitalization with ACS
s
nary syndrome (ACS) with an invasive versus conservative treatment strategy
bjects in denominators reflects those with ascertainment for the composite
nline Appendix..2 F
Deat
2 F
De
tatu
te coro
r of su
the Ozed to an invasive strategy compared with a conservative
h
d
0
1
B
w
a
b
p
S
p
i
m
f
w
s
n
0
d
a
a
b
o
t
a
c
t
i
D
T
a
i
b
F
s
i
d
S
A
m
N
a
p
g
r
h
s
p
o
m
o
s
e
p
s
p
M
c
0
A
W
M
r
e
a
a
g
i interac
M  di
109JACC Vol. 60, No. 2, 2012 O’Donoghue et al.
July 10, 2012:106–11 An Invasive Strategy in Diabetic Patientsstrategy. This early hazard was similar in both diabetic (RR:
1.27; 95% CI: 0.85 to 1.88) and nondiabetic (RR: 1.38; 95%
CI: 0.99 to 1.92) patients (p interaction  0.80). After
ospital discharge, a similar trend toward a reduction in
eath or MI was seen in both diabetic (RR: 0.78; 95% CI:
.57 to 1.08) and nondiabetic (RR: 0.77; 95% CI: 0.55 to
.07) patients (p interaction  0.72).
iomarkers and additional predictors of risk. Subjects
ith DM had a comparable reduction in death or MI with
n invasive strategy regardless of whether they also had elevated
iomarkers (creatine kinase–myocardial band or troponin;
interaction  0.65). Similarly, the presence or absence of
T-segment deviation did not appear to further identify those
atients with DM who derived a greater benefit from an
nvasive strategy (p interaction  0.83).
In contrast, among nondiabetic patients, elevated bio-
arkers identified those individuals with a greater benefit
rom an invasive strategy (RR: 0.68; 95% CI: 0.55 to 0.84),
hereas there was no apparent benefit from an invasive
trategy in patients who were nondiabetic and biomarker
egative (RR: 1.17; 95% CI: 0.89 to 1.54; p interaction 
.006). Correspondingly, the absolute risk reduction in
eath or MI with an invasive strategy was 3.7% in nondi-
betic patients with elevated biomarkers compared with an
bsolute increase in death or MI of 0.8% in patients without
iomarker elevation (p interaction  0.001). The presence
r absence of ST-segment deviation did not discriminate
hose with benefit from an invasive strategy among nondi-
betic patients (p interaction  0.14).
Figure 2 highlights the relative utility of DM status,
ardiac biomarkers, and ST-segment deviation for helping
o identify those individuals with a greater benefit with an
nvasive strategy.
iscussion
he findings of this collaborative meta-analysis suggest that
diagnosis of DM helps to identify an important subset of
Pooled 12-Month Event Numbers, RR (95% CI), and ARR (95% CI)Invasive Versus Conservative T eatment Strategy, Stratified by DMTable 2 Pooled 12-Month Event Numbers, RR (95% CI), and ARInvasive Versus Conservative Treatment Strategy, Stra
Endpoint DM Status
Invasive
Strategy
Death, MI, or rehospitalization with ACS DM 247/892
No DM 722/3,940
Death or MI DM 162/903
No DM 401/4,058
Death DM 85/903
No DM 130/4,058
Nonfatal MI DM 84/903
No DM 280/4,058
Rehospitalization with ACS DM 135/892
No DM 422/3,940
Values are n/N unless otherwise indicated. Number of subjects in denominators reflects those with a
patients: death/MI/ACS, p interaction  0.83; death/MI, p interaction  0.33; death, p interac
nteraction testing: death/MI/ACS, p interaction  0.24; death/MI, p interaction  0.27; death, p
ACS  acute coronary syndrome(s); ARR  absolute risk reduction; CI  confidence interval; Dndividuals at increased risk of adverse outcomes who may (enefit more from an invasive strategy after NSTE-ACS.
or nondiabetic individuals, additional high-risk features
uch as cardiac biomarker elevation are required to help
dentify those who benefit from an invasive approach. These
ata provide new evidence to support the updated European
ociety of Cardiology and American College of Cardiology/
merican Heart Association guidelines, which now recom-
end an invasive strategy for high-risk patients with
STE-ACS, including those with DM (1,2).
Although individuals with DM are at increased risk of
dverse outcomes after ACS (8,9), they also have a higher
revalence of comorbid conditions that may place them at
reater risk of complications after coronary angiography or
evascularization. In particular, patients with DM have a
igher prevalence of hypertension, obesity, heart failure,
troke, and impaired renal function (8). To that end,
atients with DM have been shown to be at increased risk
f short- and long-term complications, including death and
ajor adverse cardiovascular events, after percutaneous cor-
nary intervention (3) and coronary artery bypass graft
urgery compared with nondiabetic patients (4).
To date, only 2 substudies of randomized trials have
xamined the benefit of an invasive strategy in diabetic
atients. In the FRISC II (Fragmin and Fast Revasculari-
ation During Instability in Coronary Artery Disease) trial,
atients with DM had a comparable reduction in death or
I (odds ratio [OR]: 0.61; 95% CI: 0.36 to 1.04) at 1 year
ompared with nondiabetic patients (OR: 0.72; 95% CI:
.54 to 0.95) (6). Similarly, in TACTICS–TIMI 18 (Treat
ngina with Aggrastat and Determine Cost of Therapy
ith an Invasive or Conservative Strategy–Thrombolysis in
yocardial Infarction 18), an invasive strategy reduced the
isk of death, MI, or rehospitalization with ACS to a similar
xtent in diabetic patients (OR: 0.66; 95% CI: 0.46 to 0.96)
nd nondiabetic patients (OR: 0.84; 95% CI: 0.64 to 1.11),
lthough in both of these trials, there was a trend toward a
reater benefit in diabetic individuals (5). In the main ICTUS
nus5% CI) for an
by DM Status
Conservative
Strategy RR (95% CI) ARR (95% CI)
293/876 0.87 (0.73–1.03) 5.1% (0.1% to 10.2%)
874/3,934 0.86 (0.70–1.06) 3.2% (0.9% to 7.4%)
184/886 0.89 (0.68–1.16) 2.2% (3.4% to 7.9%)
406/4,057 1.04 (0.79–1.37) 0.1% (3.0% to 2.8%)
82/886 1.01 (0.70–1.45) 0.4% (4.1% to 3.2%)
128/4,057 1.00 (0.68–1.48) 0.1% (1.4% to 1.3%)
119/886 0.71 (0.55–0.92) 3.7% (1.1% to 6.3%)
294/4,057 0.98 (0.74–1.29) 0.1% (1.7% to 1.9%)
185/876 0.75 (0.61–0.92) 5.6% (2.2% to 9.1%)
599/3,934 0.75 (0.61–0.93) 3.3% (0.4% to 6.2%)
nment for the composite endpoint. Interaction testing for the RR between diabetic and nondiabetic
0.87; nonfatal MI, p interaction  0.09; rehospitalization with ACS, p interaction  0.68). ARR
tion  0.77; nonfatal MI, p interaction  0.02; rehospitalization with ACS, p interaction  0.20.
abetes mellitus; MI  myocardial infarction; RR  relative risk.for aStatR (9
tified
scertai
tion Invasive Versus Conservative Treatment in Unstable Coro-
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An Invasive Strategy in Diabetic Patients July 10, 2012:106–11nary Syndromes) publication, both diabetic and nondiabetic
patients appeared to have a similar trend that favored a
conservative (or selective invasive) strategy (10). Although
there was no heterogeneity regarding treatment benefit, indi-
vidual trials have been underpowered to detect an interaction
between subgroups.
In the current meta-analysis, we found that patients with
DM had a benefit from an invasive strategy at least
comparable to that seen in nondiabetic individuals. Impor-
tantly, our findings demonstrate that an invasive strategy
significantly reduced the risk of nonfatal MI in patients with
DM (RR: 0.71; 95% CI: 0.55 to 0.92), whereas there was
less apparent benefit in nondiabetic subjects (RR: 0.98; 95%
CI: 0.74 to 1.29; p interaction  0.09). In terms of absolute
benefit, the number of nonfatal MIs prevented with an
invasive strategy over 1 year per 1,000 diabetic patients was
37 compared with only 1 nonfatal MI prevented per 1,000
patients without DM. Among all nondiabetic patients, an
invasive strategy did not reduce the risk of death or MI (RR:
1.04; 95% CI: 0.79 to 1.37) in the absence of high-risk
features. However, the presence of elevated biomarkers was
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Figure 2 Benefit of an Invasive Strategy by High-Risk Subgroup
The relative benefit of an invasive versus conservative strategy in high-risk groups
myocardial band or troponin) or ST-segment deviation on electrocardiography. The
group and treatment arm. Relative risk (RR) (95% confidence interval [CI]) and abs
derived from random-effects models. Abbreviations as in Figure 1.highly effective at risk-stratifying those nondiabetic patientswho could derive a significant benefit from an invasive
approach.
Study limitations. As with any meta-analysis, limitations
to the methodology included heterogeneity among trials and
the possibility of publication bias. There may have been
misclassification of patients regarding their DM status.
Other factors correlated with diabetes might partially ex-
plain some of the observed differences. However, as recog-
nized by the American College of Cardiology/American
Heart Association, DM offers an easily ascertained and
validated risk factor. Tests for interactions between
subgroups were conservative and may have missed a true
interaction when one existed. As well, patient-level data
were not available, and therefore it was not possible to
explore individual-level covariates. Importantly, effect
modification was assessed at the level of each individual
trial; therefore, differences across trials should not bias
the results. Moreover, the results of the current meta-
analysis were qualitatively consistent over time and did
not change when the earliest 3 trials were excluded from
Biomarker
negative
ST deviation
positive
ST deviation
negative
Conservative
Invasive
)
8%)
RR 1.03 (0.82-1.31)
RR -0.2% (-1.9% to 1.5%)
RR 0.93 (0.69-1.24)
ARR 0.9% (-3.3 to 5.1%)
RR 1.03 (0.81-1.31)
ARR -0.2% (-2.6% to 2.2%)
ing patients with diabetes mellitus (DM), elevated biomarkers (creatine kinase-
aph displays the overall pooled incidence of death or MI at 12 months by sub-
risk reduction (ARR) (95% CI) are also shown. RR and ARR calculations wereer
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In summary, this is the first large-scale collaborative meta-
analysis to examine the effect of an invasive strategy between
diabetic and nondiabetic patients with NSTE-ACS. By
examining outcomes for 9,900 patients, we were able to
demonstrate that a routine invasive strategy significantly
reduced the 1-year incidence of MI and rehospitalization
with ACS in diabetic patients. In contrast, in nondiabetic
individuals, elevated cardiac biomarkers were an important
discriminator to help identify those who derived benefit
from a routine invasive approach. These findings suggest
that specific high-risk features such as DM and cardiac
biomarkers are useful to help identify those individuals who
will benefit from an invasive approach in NSTE-ACS.
Reprint requests and correspondence: Dr. Michelle L. O’Donoghue,
Cardiovascular Division, Brigham and Women’s Hospital, TIMI
Study Group, 350 Longwood Avenue, 1st Floor, Boston, Massachu-
setts 02115. E-mail: modonoghue@partners.org.
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